Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616000933459
Ethics application status
Approved
Date submitted
8/07/2016
Date registered
13/07/2016
Date last updated
6/07/2017
Type of registration
Prospectively registered
Titles & IDs
Public title
Assessment of the use of spironolactone on the endothelial glycocalyx in high blood pressure
Query!
Scientific title
Assessment of spironolactone on the endothelial glycocalyx in hypertension
Query!
Secondary ID [1]
289636
0
ASGARD E35-2015
Query!
Universal Trial Number (UTN)
U1111-1185-1956
Query!
Trial acronym
ASGARD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypertension
299427
0
Query!
Condition category
Condition code
Cardiovascular
299407
299407
0
0
Query!
Hypertension
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Spironolactone 25mg, oral tablet, once daily. Adherence to be monitored by questionnaire and return of empty drug packets.
Query!
Intervention code [1]
295249
0
Treatment: Drugs
Query!
Comparator / control treatment
Compared to patients receiving indapamide 2.5mg, oral tablet, daily. Adherence to be monitored by questionnaire and return of empty drug packets.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
298876
0
Change in glycocalyx parameters by:
1. Glycocheck value (sublingual camera measurement of the glycocalyx)
2. ELISA of syndecan-1 on serum samples
3. ELISA of hyaluronan on serum samples
Query!
Assessment method [1]
298876
0
Query!
Timepoint [1]
298876
0
3 months post commencement of study drug
Query!
Secondary outcome [1]
325514
0
Change in markers of endothelial dysfunction by:
1. ELISA of von Willebrand Factor on serum samples
2. ELISA of vascular cell adhesion molecule-1 (VCAM-1) on serum samples
3. Urinary microalbuminuria
Query!
Assessment method [1]
325514
0
Query!
Timepoint [1]
325514
0
3 months post commencement of study drug
Query!
Eligibility
Key inclusion criteria
Hypertension on 24-hr ambulatory blood pressure monitoring (>140/90mmHg)
and/or hypertensive event e.g. stroke
Microalbuminuria (spot urine ACR > 3 mg/mmol)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Malignancy, pregnancy, inability to consent, known haematological disorders, eGFR <60
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer software
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Based on a previously published article (Nieuwdorp et al, J Appl Physiol 2008), the number required to detect a 0.2micrometre difference in the glycocalyx for a significance level of 5% and power of 80% in a paired design (i.e. measuring outcomes before and after an intervention) is n=10. To factor in drop-outs, we plan to recruit n=15 in each arm (total 30).
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Reason for early stopping/withdrawal
Participant recruitment difficulties
Query!
Date of first participant enrolment
Anticipated
15/07/2016
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
6131
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [2]
6132
0
Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [3]
6133
0
Angliss Hospital - Upper Ferntree Gully
Query!
Recruitment postcode(s) [1]
13574
0
3128 - Box Hill
Query!
Recruitment postcode(s) [2]
13575
0
3135 - Ringwood East
Query!
Recruitment postcode(s) [3]
13576
0
3156 - Upper Ferntree Gully
Query!
Funding & Sponsors
Funding source category [1]
294016
0
University
Query!
Name [1]
294016
0
Eastern Clinical Research Unit, Monash Univeresity
Query!
Address [1]
294016
0
Level 2, 5 Arnold Street, Box Hill 3128, Victoria
Query!
Country [1]
294016
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Department of Renal Medicine, Box Hill Hospital
Query!
Address
Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria
Query!
Country
Australia
Query!
Secondary sponsor category [1]
292836
0
None
Query!
Name [1]
292836
0
Query!
Address [1]
292836
0
Query!
Country [1]
292836
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
295428
0
Eastern Health HREC
Query!
Ethics committee address [1]
295428
0
Level 2, 5 Arnold Street, Box Hill 3128, Victoria
Query!
Ethics committee country [1]
295428
0
Australia
Query!
Date submitted for ethics approval [1]
295428
0
19/05/2016
Query!
Approval date [1]
295428
0
07/07/2016
Query!
Ethics approval number [1]
295428
0
Query!
Summary
Brief summary
The glycocalyx is a particle that is important in maintaining blood vessel health. High blood pressure is common, closely related to salt regulation, and affects the health of blood vessels. Animal studies have shown that the glycocalyx is affected in high blood pressure. Laboratory studies indicate that the use of spironolactone, a common blood pressure medication, can offset the effects of a high-salt environment on the glycocalyx. The purpose of this study is to assess if the glycocalyx is affected in people who have high blood pressure, whether the glycocalyx can be improved with good blood pressure control, and whether spironolactone has any additional protective benefits on the glycocalyx.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
67274
0
Dr Hui Liew
Query!
Address
67274
0
Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria
Query!
Country
67274
0
Australia
Query!
Phone
67274
0
+61390918870
Query!
Fax
67274
0
Query!
Email
67274
0
[email protected]
Query!
Contact person for public queries
Name
67275
0
Hui Liew
Query!
Address
67275
0
Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria
Query!
Country
67275
0
Australia
Query!
Phone
67275
0
+61390918870
Query!
Fax
67275
0
Query!
Email
67275
0
[email protected]
Query!
Contact person for scientific queries
Name
67276
0
Hui Liew
Query!
Address
67276
0
Department of Renal Medicine, Box Hill Hospital, Level 2, 5 Arnold Street, Box Hill 3128, Victoria
Query!
Country
67276
0
Australia
Query!
Phone
67276
0
+61390918870
Query!
Fax
67276
0
Query!
Email
67276
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF